This page shows what was measured, who it was measured in, and what that does not settle.
What Riociguat does in the body
Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: • Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class.
Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). When NO binds to sGC, the enzyme catalyzes synthesis of the signaling molecule cyclic guanosine monophosphate (cGMP). Intracellular cGMP plays an important role in regulating processes that influence vascular tone, proliferation, fibrosis and inflammation. Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of nitric oxide and insufficient stimulation of the NO-sGC-cGMP pathway.
Why people take it. Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: • Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · RU3FE2Y4XI · read 2026-08-29
Where each sentence above came from
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 164 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 25 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Endurance
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
…Waiting for a reviewer1 registered performance measure of this kind.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Healthy ageing
…Waiting for a reviewer1 registered study measure of this kind. No reviewed result yet.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Endurance
6 minute walking distance
Healthy ageing
all cause mortality
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
… Waiting for a reviewer
1 registered performance measure of this kind.
— Not recorded
Harms were not a registered measure for this goal.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12
✗ The study did not show it
Who was studied
NCT00810693
How many people
445
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
Number of Participants With Treatment-emergent Adverse Events (TEAE)
✗ The study did not show it
Who was studied
NCT00863681
How many people
396
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16
✗ The study did not show it
Who was studied
NCT00855465
How many people
262
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
Number of Participants With Treatment-emergent Adverse Events (TEAE)
✗ The study did not show it
Who was studied
NCT00910429
How many people
237
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
Number of Participants With Satisfactory Clinical Response at Week 24
✗ The study did not show it
Who was studied
NCT02891850
How many people
225
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
Pulmonary Artery Mean Pressure (PAPmean) at Rest - Change From Baseline to Week 16
✗ The study did not show it
Who was studied
NCT01065454
How many people
202
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.2 registered measures of this kind. No reviewed result.
■What a body can do day to dayEvidence recorded. Walking, dressing, breathing, recovering.1 registered measure of this kind.
■Measured performanceEvidence recorded. How much was lifted, how far was run, how fast.1 registered measure of this kind.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.3 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Rat. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
blood pressure
heart rate from baseline
blood pressure from baseline
Meaningful
Things that change how a life goes, not only a number.
death
6 minute walking distance
all cause mortality
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (19)
safety and tolerability
treatment emergent adverse events
adverse events as a measure of safety and tolerability
pulse rate
pulmonary artery pressure
adverse events
serious adverse events
adverse drug reaction
final dose
any treatment emergent adverse events
hematology parameters from baseline
clinical chemistry from baseline
pulmonary vascular resistance
satisfactory clinical response at week 24
pulmonary arterial pressure
cardiac output
cmax
incidence of adverse events and serious adverse events
sich as per ecass iii
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 12 hours hours
Read from the label, which states: “The terminal elimination half-life is about 12 hours in patients and 7 hours in healthy subjects.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
No description of who was studied is recorded.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness of Adempas in pediatric patients have not been established [see Nonclinical Toxicology (13.2) ] .”
US prescribing information · 7b57509a-3d5d-41d4-8fed-1471e26372a3 · read 2026-08-30
On older people, the label states: “Of the total number of subjects in clinical studies of Adempas, 23% were 65 and over, and 6% were 75 and over [see Clinical Studies (14) ].”
US prescribing information · 7b57509a-3d5d-41d4-8fed-1471e26372a3 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on data from animal reproduction studies, Adempas may cause fetal harm, including birth defects and fetal death, and miscarriage when administered to a pregnant patient and is contraindicated during pregnancy [see Contraindications (4.1) ] .”
US prescribing information · 7b57509a-3d5d-41d4-8fed-1471e26372a3 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There are no data on the presence of riociguat in human milk, the effects on the breastfed infant, or the effect on milk production.”
US prescribing information · 7b57509a-3d5d-41d4-8fed-1471e26372a3 · read 2026-08-30
On people with reduced liver function, the label states: “Safety and efficacy have not been demonstrated in patients with severe hepatic impairment (Child Pugh C) [see Clinical Pharmacology (12.3) ].”
US prescribing information · 7b57509a-3d5d-41d4-8fed-1471e26372a3 · read 2026-08-30
On people with reduced kidney function, the label states: “Safety and efficacy have not been demonstrated in patients with creatinine clearance <15 mL/min or on dialysis [see Clinical Pharmacology (12.3) ].”
US prescribing information · 7b57509a-3d5d-41d4-8fed-1471e26372a3 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No form or route is recorded.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S3, S6.
No source is stored against this line.
What is in the pack
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing is recorded about product quality.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Riociguat appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 8132 reaction mentions were counted. One report can name several reactions.
The recorded terms (10)
dyspnoea — 1181 reaction mentions
hospitalisation — 963 reaction mentions
hypotension — 957 reaction mentions
headache — 938 reaction mentions
dizziness — 913 reaction mentions
nausea — 811 reaction mentions
fatigue — 726 reaction mentions
diarrhoea — 698 reaction mentions
vomiting — 494 reaction mentions
oedema peripheral — 451 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
The exact form studied is not recorded.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
17 products list this as an active ingredient in the United States drug directory. 17 of them contain it and nothing else.
FDA National Drug Code directory · 12527-0250 · read 2026-08-29
They are sold as powder and tablet, film coated, taken oral.
FDA National Drug Code directory · 12527-0250 · read 2026-08-29
The regulator's established pharmacologic class for it is guanylate cyclase stimulators [moa] and soluble guanylate cyclase stimulator [epc].
FDA National Drug Code directory · 12527-0250 · read 2026-08-29
1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 7b57509a-3d5d-41d4-8fed-1471e26372a3 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 7b57509a-3d5d-41d4-8fed-1471e26372a3 · read 2026-08-29
Adempas is oral at 3 DOSAGE FORMS AND STRENGTHS Tablets: film-coated, round, bi-convex: • 0.5 mg, white, with "BAYER" cross on one side and "0.5" and "R" on the other side • 1 mg, pale-yellow, with "BAYER" cross on one side and "1" and "R…, recorded as fda label in effect 2026-08-13 in the United States.
US prescribing information · 7b57509a-3d5d-41d4-8fed-1471e26372a3 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Riociguat studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Riociguat are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
RU3FE2Y4XI
RxNorm concept
1439821
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S3, S6.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
3 approved applications cover products containing this substance. The earliest was NDA204819, approved 20131008 to BAYER HLTHCARE.
This order is fixed in code and does not count clicks or time on the page.
What is not here
5 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (13)
Q2
What did Riociguat's largest trial (1316 people) and its longest (17 years) measure?
1316 people in Riociguat's largest registered study, 17 years in its longest registered window, measuring All-cause mortality. ClinicalTrials.gov · 2026-09-01
19 phase2, 10 phase1, 9 phase3, 8 phase4, 6 na or unstated, 4 na; NCT00694850; 2025-07-03; no ageing endpoint recorded. Last human test completed 2026, NCT03409588.
Interpretation These counts include studies where Riociguat was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
19
phase1
10
phase3
9
phase4
8
na or unstated
6
na
4
1 more recorded row
Last recorded human testNCT03409588
2026-01-26
recorded 2026-09-01 · last checked 2026-09-04
Q3
From rat to human: where has Riociguat shown lifespan?
"The sponsor terminated the study for strategic reasons. This decision was not due to safety concerns for participants receiving treatment at the time the study was terminated."; 7 of 56 registered studies
Show the evidence
Trial
NCT01065454
terminated; "The sponsor terminated the study for strategic reasons. This decision was not due to safety concerns for participants receiving treatment at the time the study was terminated."
NCT01172756
terminated; "Recruitment was only stopped after the statistical power of the study was reached and the study objectives could be met despite the premature discontinuation."
NCT02138825
terminated; "Study terminated per recommendation of iDMC. On iDMC request, protocol amended to include 4-month safety follow-up for patients after withdrawal of riociguat."
NCT02170025
terminated; "Study was terminated after completion of Part 1, because Part 2 was no longer appropriate."
NCT03273257
terminated; "The study was stopped due to slower than expected recruitment and the additional limitations on clinical research imposed by the COVID-19 pandemic, both of which made study completion within a reasonable timeframe appear unlikely."
NCT04954742
terminated; "Strategic re-prioritization by the IMP supplier. Decision not safety-related"
1 further recorded trialNCT05339087
terminated; "Strategic re-prioritization by the IMP supplier. Decision not safety-related."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Riociguat used Riociguat (Adempas, BAY63-2521) 1.0 mg — over how long?
3 recorded entries; human; also "Riociguat (Adempas, BAY63-2521) 1.0 mg", "Riociguat (Adempas, BAY63-2521) 2.5 mg", "Dose Riociguat 2,5 or 5mg"
Show the evidence
human
NCT00640315
Riociguat (Adempas, BAY63-2521) 1.0 mg
NCT00640315
Riociguat (Adempas, BAY63-2521) 2.5 mg
NCT05582811
Dose Riociguat 2,5 or 5mg
recorded 2026-09-01 · last checked 2026-09-04
Q6
Riociguat's half-life is 12 hours — which schedules were studied?
12 hours, the half-life Riociguat's label states. openfda-label · 7b57509a-3d5d-41d4-8fed-1471e26372a3 · 2026-08-30
bioavailability 94% %.
Show the evidence
half life
12 hours hours; The terminal elimination half-life is about 12 hours in patients and 7 hours in healthy subjects.
bioavailability
94% %; Absorption and distribution The absolute bioavailability of riociguat is about 94%.
metabolism
Metabolism and excretion Riociguat is mainly cleared through metabolism by CYP1A1, CYP3A4, CYP3A5 and CYP2J2.
recorded 2026-08-30 · last checked 2026-09-04
Q7
Which of 6 minute walking distance, adverse drug reaction and adverse events did Riociguat's trials measure?
6 minute walking distance, adverse drug reaction and adverse events lead 25 outcome terms across Riociguat's trials. ClinicalTrials.gov · 2026-09-01
adverse events as a measure of safety and tolerability, blood pressure, pulse rate, 6 minute walking distance, pulmonary artery pressure and adverse events follow.
Show the evidence
safety and tolerability
1
treatment emergent adverse events
1
death
1
adverse events as a measure of safety and tolerability
1
blood pressure
1
pulse rate
1
14 more recorded rows
6 minute walking distance
1
pulmonary artery pressure
1
adverse events
1
serious adverse events
1
all cause mortality
1
adverse drug reaction
1
final dose
1
any treatment emergent adverse events
1
heart rate from baseline
1
blood pressure from baseline
1
hematology parameters from baseline
1
clinical chemistry from baseline
1
pulmonary vascular resistance
1
satisfactory clinical response at week 24
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Riociguat's 6 ongoing trials reports first?
Number of Participants With Any Treatment-emergent Adverse Events; Change in stroke volume/end systolic volume (SV/ESV); latest 2028-01
Show the evidence
Trial
NCT02562235
"Riociguat in Children With Pulmonary Arterial Hypertension (PAH)"; n 24; "Number of Participants With Any Treatment-emergent Adverse Events"; 2027-08-03
NCT04062565
"Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH"; n 20; "Change in stroke volume/end systolic volume (SV/ESV)"; 2025-12-31
NCT05140525
"Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH"; n 15; "Change in end-systolic elastance (Ees) divided by arterial elastance (Ea) (Ees/Ea) at three time points: Baseline, Timepoint 1 and Timepoint 2."; 2026-12-31
NCT05825417
"Pulmonary Hypertension: Intensification and Personalisation of Combination Rx"; n 70; "Right Ventricular Stroke Volume (RVSV) flow on each therapy measured by MRI RSVS (flow) on each therapy measured by MRI"; 2028-01
NCT06715280
"Switching of Sildenafil to Riociguat in CTEPH Patients"; n 30; "Change in mean pulmonary artery pressure (mPAP)"; 2027-01-22
NCT06922240
"Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)"; n 68; "Change from Baseline in the Cardiac Output at 6 Months."; 2027-10-31
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which 21 trials of Riociguat posted no result?
Posted no result
21 of 21 completed trials
Registrations
NCT00680654, NCT04366622, NCT04364464, NCT01489488, NCT01926847 and NCT00454558, and 15 more
Completion dates
oldest 2009-11; newest 2024-02-01
Show the evidence
Trial
NCT00680654
2009-11
NCT04366622
2011-09-15
NCT04364464
2011-09-20
NCT01489488
2012-05
NCT01926847
2014-06
NCT00454558
2014-09
14 further recorded trials
NCT02159313
2015-01
NCT02159326
2015-07
NCT02545465
2016-08-31
NCT02556268
2016-12-07
NCT02007629
2016-12-29
NCT03389321
2018-02-06
NCT02092818
2018-06-29
NCT02634203
2020-01-27
NCT02744339
2020-09
NCT04211272
2021-04-19
NCT03074539
2022-12-31
NCT05582811
2023-06-01
NCT02117791
2023-09-20
NCT02428985
2023-09-20
Q10
At the median, Riociguat's trials enrolled 40 people — anything larger?
Median enrolment
40
Largest enrolment
1316
Registered trials counted
55
Q11
What do 8132 spontaneous reports say about Riociguat — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Riociguat appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 8132 reaction mentions were counted: dyspnoea 1181; hospitalisation 963; hypotension 957; headache 938. open-targets-adr · CHEMBL2107834 · 2026-06-24
Show the evidence
dyspnoea
1181
hospitalisation
963
hypotension
957
headache
938
dizziness
913
nausea
811
4 more recorded rows
fatigue
726
diarrhoea
698
vomiting
494
oedema peripheral
451
recorded 2026-06-24 · last checked 2026-09-04
Q12
Riociguat and CYP1A1, BCRP and CYP2J2: shared by which compounds?
CYP1A1, BCRP and CYP2J2 appear in Riociguat's recorded interaction sentences, 5 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP1A1
pharmacokinetics
Metabolism and excretion Riociguat is mainly cleared through metabolism by CYP1A1, CYP3A4, CYP3A5 and CYP2J2.
pharmacokinetics
Formation of the major active metabolite, M1, is catalyzed by CYP1A1, which is inducible by polycyclic aromatic hydrocarbons such as those present in cigarette smoke.
CYP2J2pharmacokinetics
Metabolism and excretion Riociguat is mainly cleared through metabolism by CYP1A1, CYP3A4, CYP3A5 and CYP2J2.
CYP3A4pharmacokinetics
Metabolism and excretion Riociguat is mainly cleared through metabolism by CYP1A1, CYP3A4, CYP3A5 and CYP2J2.
CYP3A5pharmacokinetics
Metabolism and excretion Riociguat is mainly cleared through metabolism by CYP1A1, CYP3A4, CYP3A5 and CYP2J2.
recorded 2026-08-30 · last checked 2026-09-04
Q13
Was Riociguat studied with exercise?
exercise is named in Riociguat's label sentences: "CI (2.4±0.6 L/min/m<sup>2 </sup>to 2.7±0.7 L/min/m<sup>2</sup>) and 6MWD (418.1±75.8m to 455.7±100.0m) were increased significantly. <bold> Conclusions: </bold>After<bold> </bold>long-term riociguat treatment, sequential combination with BPA delivered considerably incremental benefits on exercise…" openfda-label+europepmc · 2026-08-30
1 recorded statement; exercise
Show the evidence
exercise
CI (2.4±0.6 L/min/m<sup>2 </sup>to 2.7±0.7 L/min/m<sup>2</sup>) and 6MWD (418.1±75.8m to 455.7±100.0m) were increased significantly. <bold> Conclusions: </bold>After<bold> </bold>long-term riociguat treatment, sequential combination with BPA delivered considerably incremental benefits on exercise capacity and pulmonary hemodynamics, as well as right heart size and function of technically…
recorded 2026-08-30 · last checked 2026-09-04
Q14
What is recorded about Riociguat and autophagy?
"Notably, riociguat, a soluble guanylate cyclase stimulator approved for CTEPH, modulated autophagy-related proteins in vitro." — where Riociguat and autophagy appear together. Europe PMC · pathway abstract search · 2026-03-30
autophagy, AMPK; PMID 41912928, 32914624
Show the evidence
autophagy
PMID 41912928
"Notably, riociguat, a soluble guanylate cyclase stimulator approved for CTEPH, modulated autophagy-related proteins in vitro."
PMID 41912928
"These findings identify the TGF-β/Smad3-LC3 axis as a critical mechanism driving CTEPH and suggest that pharmacological modulation of autophagy, particularly via riociguat, offers a promising therapeutic opportunity, especially for patients ineligible for surgical intervention."
AMPKPMID 32914624
"Herein, we designed and synthesized a series of novel pyrazolo[3,4-<i>b</i>] pyridine derivatives based on sGC stimulator and AMPK inhibitor scaffolds. <i>In vitro</i>, <b>2</b> exhibited moderate vasodilation activity and higher proliferation and migration suppressive effects compared to riociguat. <i>In vivo</i>, <b>2</b> significantly decreased right ventricular systolic pressure (RVSP),…"
recorded 2026-03-30 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 9 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.